Loading peptide…
PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.
Also known as: CardioCytogen
CardioCytogen is a proprietary short-peptide bioregulator marketed for cardiovascular and heart-tissue support. It is sold as a research chemical with limited published characterization.
Sign in to rate this peptide.
CardioCytogen is positioned within the Khavinson peptide bioregulator framework, in which tissue-specific ultrashort peptides are proposed to enter cells, interact with DNA regulatory regions, and normalize gene expression in their target tissue. For a cardiac-directed bioregulator, the marketed rationale is restoration of cardiomyocyte protein synthesis, support of myocardial function, and protection against age-related and stress-induced cardiac dysfunction. Because compound-specific peer-reviewed data are limited, this mechanism is inferred from the broader cardiogen/bioregulator class rather than dedicated trials.